chartexchange

BrainsWay: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 11, 2026 7:28 AM EST

On its third-quarter 2026 earnings call, held on Nov. 10, 2026, BrainsWay (NASDAQ:BWAY) announced that its revenue grew 34% year over year to $18.1 million. The company is converting high customer demand into recurring revenue while expanding reimbursement coverage for its non-invasive brain stimulation systems. Three things management said stand out. Expanding the footprint of Deep Transcranial Magnetic Stimulation (Deep TMS), a therapy that uses magnetic fields to treat mental health disorders, generates recurring revenue through remaining performance obligations (RPO), which measure contracted revenue under multiyear customer contracts. Securing insurance coverage for SWIFT, an accelerated Deep TMS protocol that shortens treatment duration from weeks to days, increases clinic throughput and provider demand. Continue reading

Read original article